Annexon Biosciences

Compare

1,269 Followers

ANNX Stock Chart & Stats

$3.54

-$0.26(-5.25%)

At close: Jan 08 4:00 PM EST

$3.54

-$0.26(-5.25%)

Day’s Range― - ―

52-Week Range$1.29 - $7.64

Previous CloseN/A

Volume252.73K

Average Volume (3M)2.05M

Market Cap

$352.74M

Enterprise Value$156.58M

Total Cash (Recent Filing)$227.02M

Total Debt (Recent Filing)$27.63M

Price to Earnings (P/E)―

Beta2.06

Next Earnings

Nov 12, 2025

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding109,886,620

10 Day Avg. Volume1,764,491

30 Day Avg. Volume2,049,377

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.44

Enterprise Value/Revenue46.00

Enterprise Value/Gross Profit-160.43

Enterprise Value/Ebitda-0.79

Forecast

1Y Price Target

$11.60

Price Target Upside227.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEarly completion of Phase 3 enrollment for the vonaprument (ANX007) program and entry into EMA’s PRIME PDC pilot increase the credibility of the 'vision preservation' label ambition.

Financial PositionThe 2Q25 cash balance of $227M is sufficient into 2H26.

Regulatory ProgressThe EU-first pivot with an MAA in Q1 2026 is considered de-risked due to EMA's familiarity and prior deep dive.

Bears Say

Program TimelineProof-of-concept data from the oral complement inhibitor program ANX1502 is now anticipated by YE25 instead of mid-2025.

Regulatory DelaysRegulatory talks still ongoing with FDA around requirements for the BLA submission of tanruprubart in Guillain-Barré Syndrome.

Annexon Biosciences News

Annexon Biosciences’ New Study on Tanruprubart for Guillain-Barré Syndrome: A Potential Game-Changer?

Annexon Biosciences, Inc. (($ANNX)) announced an update on their ongoing clinical study. Annexon Biosciences, Inc. is conducting an...

21h ago

ANNX

Annexon Biosciences Advances AMD Treatment with ANX007 Study

Annexon Biosciences, Inc. (($ANNX)) announced an update on their ongoing clinical study. Annexon Biosciences, Inc. is conducting a...

21h ago

ANNX

Annexon participates in a conference call with JPMorgan

Conference call to address top 10 questions with management will be held on September 15 at 12:30 pm...

1M ago

ANNX

Annexon Biosciences Faces Financial Risks Amid Global Trade Challenges

Annexon Biosciences, Inc. (ANNX) has disclosed a new risk, in the Capital Markets category. Annexon Biosciences, Inc. faces...

2M ago

ANNX

Promising Outlook for Annexon Biosciences: Buy Rating Backed by Strong Pipeline and Financial Stability

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Annexon Biosciences, with a...

2M ago

ANNX

Annexon Biosciences Reports Q2 2025 Financial Results

Annexon Biosciences, Inc. ( ($ANNX) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ANNX

Annexon reports Q2 EPS (34c), consensus (36c)

Cash and cash equivalents and short-term investments were $227M as of June 30. “We are well positioned to...

2M ago

ANNX

Annexon reports Q2 EPS (34c), consensus (36c)

The company’s cash and cash equivalents and short-term investments were $227M as of June 30. It said, “We...

2M ago

ANNX

Annexon completes enrollment in Phase 3 ARCHER II trial

Annexon (ANNX) announced complete enrollment of the Phase 3 ARCHER II trial of vonaprument for dry age-related macular...

3M ago

ANNX

Annexon tells Wells Fargo doctor tweet not factural

Wells Fargo analyst Derek Archila spoke to Annexon (ANNX) as the shares traded down earlier today post the...

4M ago

ANNX

Annexon Biosciences Holds Annual Stockholders Meeting

Annexon Biosciences ( ($ANNX) ) has issued an announcement. On June 5, 2025, Annexon, Inc. conducted its Annual...

5M ago

ANNX

Annexon Biosciences: Promising Pipeline and Strategic Developments Reinforce Buy Rating

Analyst Tazeen Ahmad of Bank of America Securities reiterated a Buy rating on Annexon Biosciences (ANNX – Research...

5M ago

ANNX

Annexon presents tanruprubart data at PNS annual meeting

Annexon (ANNX) presented oral and poster presentations highlighting improved outcomes with tanruprubart at the 2025 Peripheral Nerve Society...

5M ago

ANNX

Buy Rating on Annexon Biosciences: Promising ANX005 for GBS and Strategic Path to FDA Approval

Andrew Tsai, an analyst from Jefferies, maintained the Buy rating on Annexon Biosciences (ANNX – Research Report). The...

5M ago

ANNX

ANNX FAQ

What was Annexon Biosciences’s price range in the past 12 months?

Annexon Biosciences lowest stock price was $1.28 and its highest was $7.64 in the past 12 months.

What is Annexon Biosciences’s market cap?

Annexon Biosciences’s market cap is $352.74M.

When is Annexon Biosciences’s upcoming earnings report date?

Annexon Biosciences’s upcoming earnings report date is Nov 12, 2025 which is in 15 days.

How were Annexon Biosciences’s earnings last quarter?

Annexon Biosciences released its earnings results on Aug 14, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.366 by $0.026.

Is Annexon Biosciences overvalued?

According to Wall Street analysts Annexon Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Annexon Biosciences pay dividends?

Annexon Biosciences does not currently pay dividends.

What is Annexon Biosciences’s EPS estimate?

Annexon Biosciences’s EPS estimate is -0.34.

How many shares outstanding does Annexon Biosciences have?

Annexon Biosciences has 109,886,620 shares outstanding.

What happened to Annexon Biosciences’s price movement after its last earnings report?

Annexon Biosciences reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.366. Following the earnings report the stock price went up 2.521%.

Which hedge fund is a major shareholder of Annexon Biosciences?

Currently, no hedge funds are holding shares in ANNX

Annexon Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-66.75%

Trailing 12-Months

Asset Growth

-34.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Annexon Biosciences

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Annexon Biosciences (ANNX) Earnings & Revenues

Historic Earnings Reports

ANNX Stock 12 Month Forecast

Average Price Target

$11.60

▲(227.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.9876923076923076,3.905384615384615,4.823076923076923,5.740769230769231,6.6584615384615375,7.576153846153845,8.493846153846153,9.411538461538461,10.329230769230769,11.246923076923077,12.164615384615384,13.082307692307692,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.803076923076923,3.536153846153846,4.269230769230769,5.002307692307692,5.735384615384615,6.468461538461538,7.201538461538462,7.934615384615384,8.667692307692308,9.40076923076923,10.133846153846154,10.866923076923078,{"y":11.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.603076923076923,3.136153846153846,3.6692307692307686,4.202307692307691,4.735384615384614,5.268461538461538,5.8015384615384615,6.334615384615384,6.867692307692307,7.40076923076923,7.933846153846153,8.466923076923075,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.75,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.83,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.11,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >